VRTX Vertex Pharmaceuticals Incorporated Stock Quote

VRTX [NASD]

Index	S&P 500	P/E	20.28	EPS (ttm)	10.51	Insider Own	0.20%	Shs Outstand	258.43M	Perf Week	0.61%
Market Cap	53.57B	Forward P/E	16.95	EPS next Y	12.57	Insider Trans	-13.33%	Shs Float	256.23M	Perf Month	0.21%
Income	2.76B	PEG	1.57	EPS next Q	2.73	Inst Own	95.40%	Short Float	1.91%	Perf Quarter	-0.26%
Sales	6.41B	P/S	8.35	EPS this Y	128.00%	Inst Trans	0.59%	Short Ratio	2.63	Perf Half Y	0.96%
Book/sh	33.61	P/B	6.34	EPS next Y	13.24%	ROA	25.50%	Target Price	285.09	Perf Year	-21.07%
Cash/sh	26.50	P/C	8.04	EPS next 5Y	12.90%	ROE	34.90%	52W Range	202.57 - 306.08	Perf YTD	-9.81%
Dividend	-	P/FCF	17.98	EPS past 5Y	45.30%	ROI	26.40%	52W High	-30.36%	Beta	0.66
Dividend %	-	Quick Ratio	4.20	Sales past 5Y	43.20%	Gross Margin	88.10%	52W Low	5.23%	ATR	4.25
Employees	3400	Current Ratio	4.30	Sales Q/Q	15.20%	Oper. Margin	41.50%	RSI (14)	45.01	Volatility	2.09% 1.90%
Optionable	Yes	Debt/Eq	0.07	EPS Q/Q	3.90%	Profit Margin	41.90%	Rel Volume	0.62	Prev Close	213.87
Shortable	Yes	LT Debt/Eq	0.06	Earnings	Apr 29 AMC	Payout	0.00%	Avg Volume	1.86M	Price	213.16
Recom	1.80	SMA20	-1.46%	SMA50	-0.84%	SMA200	-9.50%	Volume	1,184,101	Change	-0.33%

Feb-23-21

Upgrade

Robert W. Baird

Neutral → Outperform

$220 → $252

Feb-02-21

Reiterated

H.C. Wainwright

Buy

$315 → $275

Dec-30-20

Initiated

Daiwa Securities

Outperform

$250

Nov-30-20

Upgrade

RBC Capital Mkts

Sector Perform → Outperform

$247 → $267

Nov-20-20

Initiated

Bernstein

Outperform

$225

Oct-28-20

Initiated

UBS

Buy

$287

Jul-31-20

Reiterated

H.C. Wainwright

Buy

$295 → $315

Jul-08-20

Downgrade

Morgan Stanley

Overweight → Equal-Weight

$300

Apr-30-20

Reiterated

H.C. Wainwright

Buy

$270 → $295

Apr-28-20

Downgrade

RBC Capital Mkts

Outperform → Sector Perform

$250 → $260

Mar-04-20

Initiated

Barclays

Overweight

$271

Jan-31-20

Downgrade

Robert W. Baird

Outperform → Neutral

$210 → $230

Nov-19-19

Upgrade

Guggenheim

Neutral → Buy

$252

Nov-12-19

Initiated

SunTrust

Buy

$235

Oct-17-19

Resumed

BofA/Merrill

Buy

$220

Sep-03-19

Upgrade

Goldman

Neutral → Buy

$226 → $254

Aug-01-19

Downgrade

Needham

Buy → Hold

May-23-19

Resumed

Citigroup

Buy

$205

May-21-19

Initiated

Credit Suisse

Outperform

$209

Apr-12-19

Initiated

Evercore ISI

In-line

May-04-21 07:10AM	Was The Smart Money Right About Vertex Pharmaceuticals (VRTX)? Insider Monkey
06:00AM	This Bold Statement by the Vertex CEO Means a New Blockbuster May be Here Soon Motley Fool
May-01-21 06:30AM	Forget Penny Stocks: Buy These 2 Stocks Instead Motley Fool
06:10AM	Will Vertex's Sickle Cell Gambit Sink bluebird bio's Stock? Motley Fool
Apr-30-21 08:12AM	Vertex (VRTX) Q1 Earnings Beat Estimates, Revenues Up Y/Y Zacks
06:50AM	Have $1,000 to Invest? Buy These 2 Growth Stocks Right Now Motley Fool
06:05AM	Here's How Vertex Pharmaceuticals Beat Expectations in Q1 Motley Fool
06:01AM	3 of Cathie Wood's Biggest Losers of 2021 That Should Still Be Huge Long-Term Winners Motley Fool
Apr-29-21 10:01PM	Vertex Pharmaceuticals Inc (VRTX) Q1 2021 Earnings Call Transcript Motley Fool
05:25PM	Vertex Pharmaceuticals (VRTX) Q1 Earnings and Revenues Surpass Estimates Zacks
05:00PM	Vertex Stock Muted After Beating Quarterly Views; What Could Spark Shares? Investor's Business Daily
04:01PM	Vertex Reports First-Quarter 2021 Financial Results Business Wire
Apr-28-21 12:18PM	Biotech Stock Roundup: BIIB, AMGN's Q1 Earnings Updates & Other Pipeline News Zacks
09:56AM	CRISPR Therapeutics (CRSP) Q1 Earnings Miss, Revenues Rise Y/Y Zacks
07:30AM	Vertex Announces European Commission Approval for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Cystic Fibrosis Patients 12 Years and Older With At Least One F508del Mutation in the CFTR gene Business Wire
Apr-26-21 02:47PM	Skyworks Lifts Nasdaq Ahead of Earnings; CRISPR Keeps Moving Forward Motley Fool
09:54AM	What's in Store for Vertex (VRTX) This Earnings Season? Zacks
08:30AM	Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001 for Transfusion-Dependent Beta Thalassemia GlobeNewswire
07:29AM	Vertex Announces NaV1.8 Inhibitor Advancing to Phase 2 Clinical Development Business Wire
Apr-25-21 06:00AM	3 Top Biotech Picks to Buy and Hold for the Next 10 Years Motley Fool
Apr-23-21 08:09AM	Is a Beat in Store for CRISPR (CRSP) This Earnings Season? Zacks
06:25AM	Is Vertex Pharmaceuticals a Good Stock to Buy Right Now? Motley Fool
Apr-22-21 12:33PM	Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth Zacks
09:06AM	Vertex Pharma Inks Research, Licensing Agreement With Obsidian Therapeutics For Controllable Genetic Therapies Benzinga
08:00AM	Vertex and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editing Business Wire
Apr-21-21 02:54PM	Biotech Stock Roundup: BMYs Opdivo Gets FDA Nod for Gastric Cancer & Other Updates Zacks
08:55AM	Vertex (VRTX) Ups Investment in CRISPR Gene Therapy Partnership Zacks
07:59AM	Vertex to study experimental gene-editing therapy as treatment for sickle cell, beta-thalassemia MarketWatch
06:40AM	3 Top Value Stocks in Healthcare to Buy Right Now Motley Fool
Apr-20-21 05:50PM	Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know Zacks
04:29PM	Vertex Pharmaceuticals Raises Bet on CRISPR Therapeutics Motley Fool
07:15AM	Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001 in Sickle Cell Disease and Beta Thalassemia GlobeNewswire
Apr-19-21 09:01AM	Vertex to Announce First-Quarter 2021 Financial Results on April 29 Business Wire
Apr-18-21 06:06AM	The Growth Stock Sale of 2021 Has Arrived: 3 Stocks to Buy Now Motley Fool
Apr-17-21 09:01AM	A Star-Laden Biotech SPAC Worth Considering Motley Fool
07:00AM	3 Cathie Wood Stocks You Can Buy at a Bargain Right Now Motley Fool
Apr-16-21 09:12AM	The Vertex Pharmaceuticals (NASDAQ:VRTX) Share Price Is Up 155% And Shareholders Are Boasting About It Simply Wall St.
06:04AM	4 Cathie Wood Stocks That Could Deliver Bigger Gains Than Tesla Motley Fool
Apr-14-21 05:50PM	Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know Zacks
Apr-13-21 05:50AM	5 Value Stocks With 26% to 50% Upside, According to Wall Street Motley Fool
Apr-11-21 09:03AM	3 Critical Things Investors Should Look for Before Buying Clinical-Stage Biotech Stocks Motley Fool
Apr-08-21 04:20PM	Biotech Stocks Could Use A Win Will The First Quarter Offer That? Investor's Business Daily
Apr-07-21 06:01AM	3 Top Biotech Stocks to Buy in April Motley Fool
Apr-05-21 05:51AM	3 Value Stocks That'll Make You Richer in April (and Beyond) Motley Fool
Apr-02-21 08:06AM	Here's the Holy Grail of Gene Editing Motley Fool
Mar-31-21 01:33PM	Biotech Stock Roundup: BLUE/BMY's CAR T Therapy Nod, KLDO's COVID-19 Study News & More Zacks
Mar-28-21 06:01AM	3 Top Biotech Stocks to Buy Right Now Motley Fool
Mar-26-21 07:23AM	Vertex Receives CHMP Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With Cystic Fibrosis With At Least One F508del Mutation Business Wire
Mar-24-21 07:21PM	Vertex Receives Australian TGA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat People With Cystic Fibrosis Ages 12 Years and Older Who Have At Least One F508del Mutation Business Wire
05:50PM	Vertex Pharmaceuticals (VRTX) Dips More Than Broader Markets: What You Should Know Zacks
08:19AM	The Zacks Analyst Blog Highlights: Abbott Laboratories, AstraZeneca, Booking, Vertex Pharmaceuticals and Yum China Zacks
Mar-23-21 02:38PM	Top Analyst Reports for Abbott, AstraZeneca & Booking Holdings Zacks
10:12AM	Is VRTX Stock A Buy or Sell? Insider Monkey
Mar-22-21 06:04AM	3 Stocks Cathie Wood Likes That Should Make You Rich Motley Fool
Mar-20-21 06:30AM	2 Top Growth Stocks That Could Make You Richer in March (And Beyond) Motley Fool
06:04AM	3 Top Healthcare Stocks to Buy Right Now Motley Fool
Mar-17-21 11:48AM	Here Are 5 Undervalued Biopharma Stocks Barrons.com
Mar-16-21 12:19PM	Heres Why Vertex (VRTX) Landed in Alger Spectras Detractor List Insider Monkey
08:24AM	Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong? Simply Wall St.
Mar-14-21 06:18AM	3 Top Biotech Stocks to Buy in March Motley Fool
05:51AM	5 Disruptive Stocks to Buy for a Biden Bull Market Motley Fool
Mar-11-21 05:45PM	Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should Know Zacks
08:52AM	Vertex (VRTX) Type I Diabetes Candidate Clinical Study Begins Zacks
Mar-10-21 01:04PM	Vertex to begin Phase 1/2 trial of treatment for people with type 1 diabetes MarketWatch
07:55AM	Vertex Announces FDA Fast Track Designation and Initiation of a Phase 1/2 Clinical Trial for VX-880, a Novel Investigational Cell Therapy for the Treatment of Type 1 Diabetes Business Wire
Mar-09-21 10:25AM	Quant Genius Billionaire Jim Simons Top 10 Stock Picks Insider Monkey
06:06AM	5 Stocks to Watch Amid Continued Expansion in the Biotech Industry Zacks
Mar-07-21 07:19AM	Barron's Latest Picks And Pans: Lowe's, Microsoft, Vertex Pharmaceuticals, ViacomCBS And More Benzinga
06:06AM	Forget GameStop, AMC, and Sundial: These Are the Best Stocks to Buy Right Now Motley Fool
Mar-05-21 07:00AM	Vertex Stock Fell After a Setback on a New Drug. Its an Opportunity for Investors. Barrons.com
Mar-03-21 11:30AM	Vertex (VRTX) Down 2.4% Since Last Earnings Report: Can It Rebound? Zacks
Mar-02-21 05:51AM	3 Growth Stocks That'll Make You Richer in March (and Beyond) Motley Fool
Feb-24-21 09:01AM	Vertex to Present at the Cowen Health Care Conference on March 2 Business Wire
Feb-21-21 06:36AM	Forget Bitcoin: 4 Stocks to Buy Hand Over Fist Instead Motley Fool
Feb-20-21 07:10AM	What Should Vertex Pharmaceuticals Buy With its $6.6 Billion Stash? Motley Fool
Feb-19-21 07:50AM	Here's Why Vertex Pharmaceuticals' Fourth Quarter Was Better Than It First Appeared Motley Fool
Feb-18-21 12:49PM	Is Vertex Pharmaceuticals (VRTX) Stock a Buy For 2021? Insider Monkey
Feb-17-21 02:00PM	Here's What Caused Royalty Pharma's Mixed Results in Q4 Motley Fool
08:19AM	Wall Street Looks Again at Bluebird, Rivals, After Gene-Therapy Setback Barrons.com
Feb-15-21 06:22AM	3 Healthcare Stocks I'd Buy Right Now Motley Fool
Feb-14-21 05:51AM	5 Sizzling Growth Stocks to Buy for a Biden Bull Market Motley Fool
Feb-11-21 08:53AM	Should You Take Comfort From Insider Transactions At Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)? Simply Wall St.
Feb-06-21 05:36PM	Top 10 Large-Cap Healthcare Stocks to Buy Now Insider Monkey
Feb-05-21 09:32AM	CRISPR (CRSP) to Report Q4 Earnings: What's in the Cards? Zacks
07:55AM	3 Reasons It's Not Too Late to Buy Vertex Pharmaceuticals Motley Fool
Feb-03-21 10:25AM	Biotech Stock Roundup: AMGN, VRTX Q4 Results, SAVA's Encouraging Drug Data & More Zacks
06:10AM	Ignore GameStop: Here Are 3 Better Stocks Motley Fool
Feb-02-21 04:35PM	Why Vertex Pharmaceuticals Stock Fell Today Motley Fool -6.23%
10:26AM	Vertex CEO says company is seeking to make 'transformative' deals MarketWatch
10:25AM	Vertex (VRTX) Q4 Earnings Miss, Revenues Beat Estimates Zacks
06:03AM	Why Vertex Pharmaceuticals' Solid Q4 Results Weren't Good Enough Motley Fool
Feb-01-21 10:30PM	Vertex Pharmaceuticals Inc (VRTX) Q4 2020 Earnings Call Transcript Motley Fool
05:56PM	Markets Snap Back into Bullish Territory Zacks
05:25PM	Vertex Pharmaceuticals (VRTX) Lags Q4 Earnings Estimates Zacks
04:53PM	Vertex Stock Dips On Mixed Report; Investors Eye Its Next Catalysts Investor's Business Daily
04:39PM	Vertex Pharmaceuticals: Q4 Earnings Insights Benzinga
04:01PM	Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results Business Wire
02:30PM	Vertex Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
06:06AM	3 Top Stocks That'll Make You Richer in February (and Beyond) Motley Fool
05:43AM	Zacks.com featured highlights include: Crocs, AGCO, Meritage Homes and Vertex Pharmaceuticals Zacks

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics, as well as a strategic research collaboration and licensing agreement with Obsidian Therapeutics, Inc. for the discovery of novel therapies that regulate gene editing for the treatment of serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sanna Bastiano	EVP, Cell & Genetic Therapies	May 03	Sale	218.43	960	209,691	34,108	May 05 09:23 PM
Sachdev Amit	EVP, Chief Patient Officer	Apr 27	Option Exercise	86.52	3,884	336,044	44,017	Apr 29 04:03 PM
Sachdev Amit	EVP, Chief Patient Officer	Apr 27	Sale	216.06	3,884	839,193	40,133	Apr 29 04:03 PM
Sanna Bastiano	EVP, Cell & Genetic Therapies	Apr 05	Sale	214.14	1,686	361,046	35,834	Apr 07 04:04 PM
Liu Joy	SVP, General Counsel	Mar 05	Sale	209.69	5,141	1,078,018	8,253	Mar 08 04:10 PM
Silva Paul M	SVP & Chief Accounting Officer	Mar 01	Sale	211.45	2,782	588,255	9,884	Mar 02 04:07 PM
Silva Paul M	SVP & Chief Accounting Officer	Feb 25	Sale	213.47	1,080	230,551	14,884	Feb 26 04:23 PM
Sachdev Amit	EVP, Chief Patient Officer	Feb 25	Sale	213.42	3,586	765,307	40,133	Feb 26 04:20 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Feb 25	Sale	213.38	3,028	646,125	30,837	Feb 26 04:18 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Feb 25	Sale	213.54	3,634	775,989	41,103	Feb 26 04:07 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Feb 25	Sale	213.39	3,028	646,139	33,589	Feb 26 04:03 PM
Silva Paul M	SVP & Chief Accounting Officer	Feb 18	Sale	211.83	4,295	909,828	16,828	Feb 19 04:21 PM
Sachdev Amit	EVP, Chief Patient Officer	Feb 18	Sale	211.83	9,264	1,962,366	46,665	Feb 19 04:20 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Feb 18	Sale	211.83	7,825	1,657,556	36,281	Feb 19 04:18 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Feb 18	Sale	211.82	7,825	1,657,481	47,635	Feb 19 04:08 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Feb 18	Sale	211.83	7,825	1,657,590	39,033	Feb 19 04:05 PM
Sachdev Amit	EVP, Chief Patient Officer	Feb 11	Sale	210.55	4,460	939,068	63,542	Feb 16 04:20 PM
Silva Paul M	SVP & Chief Accounting Officer	Feb 11	Sale	210.57	1,498	315,437	23,863	Feb 16 04:24 PM
Sanna Bastiano	EVP, Cell & Genetic Therapies	Feb 11	Sale	210.56	1,686	355,012	38,864	Feb 16 04:22 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Feb 11	Sale	210.56	4,318	909,179	50,346	Feb 16 04:15 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Feb 11	Sale	210.55	5,156	1,085,593	61,700	Feb 16 04:07 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Feb 11	Sale	210.54	5,283	1,112,274	53,098	Feb 16 04:02 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Feb 05	Option Exercise	86.52	1,930	166,984	59,157	Feb 09 07:44 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Feb 05	Sale	215.00	1,930	414,950	57,227	Feb 09 07:44 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Feb 03	Option Exercise	86.52	1,554	134,452	71,511	Feb 05 04:43 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Feb 03	Option Exercise	86.52	400	34,608	57,627	Feb 05 04:52 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Feb 03	Sale	216.56	400	86,624	57,227	Feb 05 04:52 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Feb 03	Sale	213.74	1,554	332,146	69,957	Feb 05 04:43 PM
Sachdev Amit	EVP, Chief Patient Officer	Nov 16	Sale	223.53	42	9,388	35,103	Nov 18 04:16 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Nov 16	Sale	223.53	91	20,341	26,838	Nov 18 04:12 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Nov 16	Sale	223.64	7	1,565	35,179	Nov 18 04:11 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Nov 16	Sale	223.47	38	8,492	28,902	Nov 18 04:10 PM
SACHS BRUCE I	Director	Nov 10	Buy	217.36	15,000	3,260,465	26,210	Nov 12 08:18 AM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Nov 04	Option Exercise	86.52	2,330	201,592	29,168	Nov 06 04:09 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Nov 04	Sale	217.74	2,330	507,329	26,838	Nov 06 04:09 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Nov 03	Option Exercise	86.52	1,553	134,366	36,732	Nov 05 04:16 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Nov 03	Sale	211.92	1,553	329,115	35,179	Nov 05 04:16 PM
Bhatia Sangeeta N.	Director	Oct 05	Option Exercise	126.68	8,729	1,105,790	14,424	Oct 07 04:11 PM
Bhatia Sangeeta N.	Director	Oct 05	Sale	266.79	10,516	2,805,518	3,908	Oct 07 04:11 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Aug 06	Option Exercise	155.57	1,223	190,262	30,125	Aug 10 04:13 PM
Kewalramani Reshma	CEO & President	Aug 06	Option Exercise	179.68	2,073	372,482	28,699	Aug 10 04:19 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Aug 06	Option Exercise	155.57	1,223	190,262	28,061	Aug 10 04:22 PM
Silva Paul M	SVP & Controller	Aug 06	Option Exercise	169.39	1,078	182,598	16,010	Aug 10 04:24 PM
Silva Paul M	SVP & Controller	Aug 06	Sale	271.17	1,078	292,319	14,932	Aug 10 04:24 PM
Kewalramani Reshma	CEO & President	Aug 06	Sale	271.20	2,073	562,205	26,626	Aug 10 04:19 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Aug 06	Sale	271.19	1,223	331,663	28,902	Aug 10 04:13 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Aug 06	Sale	271.20	1,223	331,672	26,838	Aug 10 04:22 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Aug 03	Option Exercise	86.52	2,330	201,592	31,232	Aug 05 04:14 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Aug 03	Option Exercise	86.52	1,553	134,366	36,732	Aug 05 04:17 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Aug 03	Option Exercise	86.52	2,330	201,592	29,168	Aug 05 04:20 PM
Silva Paul M	SVP & Controller	Aug 03	Option Exercise	86.52	809	69,995	15,741	Aug 05 04:24 PM
Sachdev Amit	EVP, Chief Patient Officer	Aug 03	Option Exercise	86.52	1,941	167,935	37,044	Aug 05 04:51 PM
Silva Paul M	SVP & Controller	Aug 03	Sale	278.30	809	225,142	14,932	Aug 05 04:24 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Aug 03	Sale	278.28	2,330	648,402	26,838	Aug 05 04:20 PM
Sachdev Amit	EVP, Chief Patient Officer	Aug 03	Sale	278.28	1,941	540,137	35,103	Aug 05 04:51 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Aug 03	Sale	278.39	1,553	432,337	35,179	Aug 05 04:17 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Aug 03	Sale	278.24	2,330	648,290	28,902	Aug 05 04:14 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Jul 13	Option Exercise	90.29	2,125	191,866	28,963	Jul 15 04:41 PM
Silva Paul M	SVP & Controller	Jul 13	Option Exercise	90.29	860	77,649	15,792	Jul 15 04:51 PM
Silva Paul M	SVP & Controller	Jul 13	Sale	292.03	860	251,145	14,932	Jul 15 04:51 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Jul 13	Sale	292.05	2,125	620,610	26,838	Jul 15 04:41 PM
WAGNER CHARLES F JR	EVP & Chief Financial Officer	Jul 10	Sale	293.15	700	205,206	16,126	Jul 14 04:16 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Jul 07	Option Exercise	173.51	2,786	483,403	37,965	Jul 09 04:13 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Jul 07	Sale	300.00	2,786	835,800	35,179	Jul 09 04:13 PM
LEIDEN JEFFREY M	Executive Chairman	Jun 30	Sale	286.15	32,792	9,383,304	2,261	Jul 02 04:15 PM
Bhatia Sangeeta N.	Director	Jun 02	Sale	282.88	952	269,298	5,695	Jun 03 04:22 PM
Kewalramani Reshma	CEO & President	May 15	Sale	284.17	99	28,132	26,626	May 19 04:35 PM
Tatsis Ourania	EVP, Chief Regulatory Officer	May 15	Sale	284.00	120	34,080	12,738	May 19 04:33 PM
Silva Paul M	SVP & Controller	May 15	Sale	284.00	151	42,885	14,932	May 19 04:31 PM
Sachdev Amit	EVP, Chief Patient Officer	May 15	Sale	284.41	58	16,496	35,103	May 19 04:29 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	May 15	Sale	284.40	68	19,339	26,838	May 19 04:28 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	May 15	Sale	283.98	113	32,089	35,179	May 19 04:22 PM
ALTSHULER DAVID	EVP, Global Research and CSO	May 15	Sale	284.37	82	23,318	28,902	May 19 04:21 PM
ALTSHULER DAVID	EVP, Global Research and CSO	May 12	Option Exercise	187.53	1,304	244,539	30,206	May 14 04:17 PM
LEIDEN JEFFREY M	Executive Chairman	May 12	Option Exercise	137.52	88,532	12,174,639	129,353	May 14 04:19 PM
LEIDEN JEFFREY M	Executive Chairman	May 12	Sale	283.47	94,370	26,751,440	34,983	May 14 04:19 PM
ALTSHULER DAVID	EVP, Global Research and CSO	May 12	Sale	287.33	1,304	374,678	28,902	May 14 04:17 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	May 11	Option Exercise	187.53	1,304	244,539	28,142	May 13 04:18 PM
Sachdev Amit	EVP, Chief Patient Officer	May 11	Option Exercise	131.89	10,665	1,406,607	45,768	May 13 04:20 PM
Sachdev Amit	EVP, Chief Patient Officer	May 11	Sale	282.61	10,665	3,014,014	35,103	May 13 04:20 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	May 11	Sale	286.00	1,304	372,944	26,838	May 13 04:18 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience